• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PXS
Click for more information
0.00% 8.5¢

PHARMAXIS LTD - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
PXSPharmaxis Announces Delay to French Pricing for BronchitolPRICE SENSITIVE29/08/13
PXSPreliminary Final ReportPRICE SENSITIVE15/08/13
PXSChange in substantial holding01/08/13
PXSAppendix 3B - Exercise of employee options29/07/13
PXSPHARMAXIS ANNOUNCES IMPROVED PBS LISTING OF BRONCHITOLPRICE SENSITIVE18/07/13
PXSAppendix 4C - quarterlyPRICE SENSITIVE17/07/13
PXSInvestor Presentation - Quarterly Briefing June 201317/07/13
PXSPHARMAXIS QUARTERLY INVESTOR CONFERENCE CALL16/07/13
PXSPharmaxis Awarded Two ARC Linkage GrantsPRICE SENSITIVE05/07/13
PXSEuropean CF Clinical Trial in Paediatric Patients BeginsPRICE SENSITIVE20/06/13
PXSPharmaxis Presents New Analyses of Pooled CF Data at EU MeetPRICE SENSITIVE18/06/13
PXSApp 3B - Grant of employee Options07/06/13
PXSCEO Remuneration and Employee Performance Rights07/06/13
PXSAridol FDA Import RestrictionsPRICE SENSITIVE03/06/13
PXSInvestor Presentation - Business Plan28/05/13
PXSOutcome of Business ReviewPRICE SENSITIVE28/05/13
PXSInvestor Conference Call - Results of Business Plan23/05/13
PXSPharmaxis Appoints Bronchitol Distributor for PolandPRICE SENSITIVE22/05/13
PXSPharmaxis Agrees Key Cystic Fibrosis Trial Paramaters with F21/05/13
PXSCeasing to be a substantial holder20/05/13
PXSCeasing to be a substantial holder17/05/13
PXSFDA Meeting, Business Review Announcement End of MayPRICE SENSITIVE14/05/13
PXSBecoming a substantial holder06/05/13
PXSChange of Director's Interest Notice03/05/13
PXSCeasing to be a substantial holder29/04/13
PXSInvestor presentation - B30524/04/13
PXSPHASE 3 CLINICAL TRIAL IN BRONCHIECTASIS (B305)PRICE SENSITIVE24/04/13
PXSPharmaxis Conference Call23/04/13
PXSTrading HaltPRICE SENSITIVE22/04/13
PXSChange in substantial holding15/04/13
PXSAppendix 4C - quarterlyPRICE SENSITIVE10/04/13
PXSInvestor Presentation - April 201310/04/13
PXSPharmaxis Announces Bronchitol Distributor for Brazil10/04/13
PXSQuarterly Investor Conference Call10/04/13
PXSPHARMAXIS RECEIVES COMPLETE RESPONSE LETTER FROM FDAPRICE SENSITIVE19/03/13
PXSTrading HaltPRICE SENSITIVE19/03/13
PXSInitial Director's Interest Notice12/03/13
PXSFinal Director's Interest Notice12/03/13
PXSPharmaxis Appoints Gary Phillips New Chief Executive OfficerPRICE SENSITIVE12/03/13
PXSBronchiectasis Phase 3 Trial MilestonePRICE SENSITIVE08/03/13
PXSHalf Year Report and AccountsPRICE SENSITIVE15/02/13
PXSBecoming a substantial holder04/02/13
PXSPharmaxis Announces US$40 million Financing AreementPRICE SENSITIVE31/01/13
PXSPharmaxis Receives Negative Recommendation from PADACPRICE SENSITIVE31/01/13
PXSTrading HaltPRICE SENSITIVE29/01/13
PXSDecember 2012 Quarterly Report to Shareholders23/01/13
PXSAppendix 4C - quarterlyPRICE SENSITIVE23/01/13
PXSInvestor Conference Call and Quarterly Report22/01/13
PXSAppendix 3B - Exercise of Employee Options13/11/12
PXSAppendix 3B - Exercise of Employee Options08/11/12
PXSAppendix 3B - Option Exercise30/10/12
PXSIMPORTANT MILESTONE BRONCHITOL APPROVED BY NICE IN UKPRICE SENSITIVE26/10/12
PXSTrading HaltPRICE SENSITIVE26/10/12
PXSChange of Director's Interest Notice18/10/12
PXSChange of Director's Interest Notice18/10/12
PXSAppendix 3B - Option Issue18/10/12
PXSResults of Meeting18/10/12
PXSCEO Presentation to AGM17/10/12
PXSChairman's Address to Shareholders17/10/12
PXSSeptember 2012 Quarterly Report to Sharehholders10/10/12
PXSAppendix 4C - quarterlyPRICE SENSITIVE10/10/12
PXSPresentation at North American Cystic Fibrosis Conference10/10/12
PXSQuarterly Report and Investor Conference Call08/10/12
PXSResponse to ASX Price QueryPRICE SENSITIVE08/10/12
PXSPharmaxis Receives Maximum Extension to German PatentPRICE SENSITIVE27/09/12
PXSInvestor Presentation13/09/12
PXSAnnual Report to shareholders 201211/09/12
PXSNotice of Annual General Meeting/Proxy Form 201211/09/12
PXSInvestor Presentation16/08/12
PXSIndependent Audit Report - 30 June 201210/08/12
PXSProposed Grant of Options to New Director10/08/12
PXSAppendix 3B - Employee Shares10/08/12
PXSPreliminary Final ReportPRICE SENSITIVE10/08/12
PXSUS FDA Accepts Bronchitol New Drug Application for ReviewPRICE SENSITIVE02/08/12
PXSInitial Director's Interest Notice25/07/12
PXSPharmaxis Announces New Board Appointment25/07/12
PXSAppendix 3B - Exercise of Employee Options24/07/12
PXSQuarterly Report to Shareholders - June 201217/07/12
PXSAppendix 4C - quarterlyPRICE SENSITIVE17/07/12
PXSPharmaxis Quarterly Investor Conference Call16/07/12
PXSCeasing to be a substantial holder10/07/12
PXSBecoming a substantial holder05/07/12
PXSCeasing to be a substantial holder04/07/12
PXSProposed Issue of Performance Rights to CEO02/07/12
PXSAppendix 3B - Grant of Employee Performance Rights02/07/12
PXSAppendix 3B - Exercise of Employee Options02/07/12
PXS +Becoming a substantial holder from UBS29/06/12
PXSChange of Director's Interest Notice28/06/12
PXSAppendix 3B28/06/12
PXSPHARMAXIS WELCOMES BRONCHITOL PBS LISTING ANNOUNCEMENT25/06/12
PXSCeasing to be a substantial holder19/06/12
PXSBecoming a substantial holder15/06/12
PXSAdditional Data Bronchitol Reduces Risk of ExacerbationsPRICE SENSITIVE08/06/12
PXSAppendix 3B - Exercise of Employee Options01/06/12
PXSBronchitol Commercial Progress in EuropePRICE SENSITIVE01/06/12
PXSAppendix 3B - Exercise of employee options21/05/12
PXSPharmaxis Submits US New Drug Application for BronchitolPRICE SENSITIVE21/05/12
PXSAmended - Ceasing to be a substantial holder16/05/12
PXSCeasing to be a substantial holder10/05/12
PXSAppendix 3B Exercise of Employee Options02/05/12
PXSPharmaxis Announces Delay to French Pricing for Bronchitol
29/08/13PRICE SENSITIVE
PXSPreliminary Final Report
15/08/13PRICE SENSITIVE
PXSChange in substantial holding
01/08/13
PXSAppendix 3B - Exercise of employee options
29/07/13
PXSPHARMAXIS ANNOUNCES IMPROVED PBS LISTING OF BRONCHITOL
18/07/13PRICE SENSITIVE
PXSAppendix 4C - quarterly
17/07/13PRICE SENSITIVE
PXSInvestor Presentation - Quarterly Briefing June 2013
17/07/13
PXSPHARMAXIS QUARTERLY INVESTOR CONFERENCE CALL
16/07/13
PXSPharmaxis Awarded Two ARC Linkage Grants
05/07/13PRICE SENSITIVE
PXSEuropean CF Clinical Trial in Paediatric Patients Begins
20/06/13PRICE SENSITIVE
PXSPharmaxis Presents New Analyses of Pooled CF Data at EU Meet
18/06/13PRICE SENSITIVE
PXSApp 3B - Grant of employee Options
07/06/13
PXSCEO Remuneration and Employee Performance Rights
07/06/13
PXSAridol FDA Import Restrictions
03/06/13PRICE SENSITIVE
PXSInvestor Presentation - Business Plan
28/05/13
PXSOutcome of Business Review
28/05/13PRICE SENSITIVE
PXSInvestor Conference Call - Results of Business Plan
23/05/13
PXSPharmaxis Appoints Bronchitol Distributor for Poland
22/05/13PRICE SENSITIVE
PXSPharmaxis Agrees Key Cystic Fibrosis Trial Paramaters with F
21/05/13
PXSCeasing to be a substantial holder
20/05/13
PXSCeasing to be a substantial holder
17/05/13
PXSFDA Meeting, Business Review Announcement End of May
14/05/13PRICE SENSITIVE
PXSBecoming a substantial holder
06/05/13
PXSChange of Director's Interest Notice
03/05/13
PXSCeasing to be a substantial holder
29/04/13
PXSInvestor presentation - B305
24/04/13
PXSPHASE 3 CLINICAL TRIAL IN BRONCHIECTASIS (B305)
24/04/13PRICE SENSITIVE
PXSPharmaxis Conference Call
23/04/13
PXSTrading Halt
22/04/13PRICE SENSITIVE
PXSChange in substantial holding
15/04/13
PXSAppendix 4C - quarterly
10/04/13PRICE SENSITIVE
PXSInvestor Presentation - April 2013
10/04/13
PXSPharmaxis Announces Bronchitol Distributor for Brazil
10/04/13
PXSQuarterly Investor Conference Call
10/04/13
PXSPHARMAXIS RECEIVES COMPLETE RESPONSE LETTER FROM FDA
19/03/13PRICE SENSITIVE
PXSTrading Halt
19/03/13PRICE SENSITIVE
PXSInitial Director's Interest Notice
12/03/13
PXSFinal Director's Interest Notice
12/03/13
PXSPharmaxis Appoints Gary Phillips New Chief Executive Officer
12/03/13PRICE SENSITIVE
PXSBronchiectasis Phase 3 Trial Milestone
08/03/13PRICE SENSITIVE
PXSHalf Year Report and Accounts
15/02/13PRICE SENSITIVE
PXSBecoming a substantial holder
04/02/13
PXSPharmaxis Announces US$40 million Financing Areement
31/01/13PRICE SENSITIVE
PXSPharmaxis Receives Negative Recommendation from PADAC
31/01/13PRICE SENSITIVE
PXSTrading Halt
29/01/13PRICE SENSITIVE
PXSDecember 2012 Quarterly Report to Shareholders
23/01/13
PXSAppendix 4C - quarterly
23/01/13PRICE SENSITIVE
PXSInvestor Conference Call and Quarterly Report
22/01/13
PXSAppendix 3B - Exercise of Employee Options
13/11/12
PXSAppendix 3B - Exercise of Employee Options
08/11/12
PXSAppendix 3B - Option Exercise
30/10/12
PXSIMPORTANT MILESTONE BRONCHITOL APPROVED BY NICE IN UK
26/10/12PRICE SENSITIVE
PXSTrading Halt
26/10/12PRICE SENSITIVE
PXSChange of Director's Interest Notice
18/10/12
PXSChange of Director's Interest Notice
18/10/12
PXSAppendix 3B - Option Issue
18/10/12
PXSResults of Meeting
18/10/12
PXSCEO Presentation to AGM
17/10/12
PXSChairman's Address to Shareholders
17/10/12
PXSSeptember 2012 Quarterly Report to Sharehholders
10/10/12
PXSAppendix 4C - quarterly
10/10/12PRICE SENSITIVE
PXSPresentation at North American Cystic Fibrosis Conference
10/10/12
PXSQuarterly Report and Investor Conference Call
08/10/12
PXSResponse to ASX Price Query
08/10/12PRICE SENSITIVE
PXSPharmaxis Receives Maximum Extension to German Patent
27/09/12PRICE SENSITIVE
PXSInvestor Presentation
13/09/12
PXSAnnual Report to shareholders 2012
11/09/12
PXSNotice of Annual General Meeting/Proxy Form 2012
11/09/12
PXSInvestor Presentation
16/08/12
PXSIndependent Audit Report - 30 June 2012
10/08/12
PXSProposed Grant of Options to New Director
10/08/12
PXSAppendix 3B - Employee Shares
10/08/12
PXSPreliminary Final Report
10/08/12PRICE SENSITIVE
PXSUS FDA Accepts Bronchitol New Drug Application for Review
02/08/12PRICE SENSITIVE
PXSInitial Director's Interest Notice
25/07/12
PXSPharmaxis Announces New Board Appointment
25/07/12
PXSAppendix 3B - Exercise of Employee Options
24/07/12
PXSQuarterly Report to Shareholders - June 2012
17/07/12
PXSAppendix 4C - quarterly
17/07/12PRICE SENSITIVE
PXSPharmaxis Quarterly Investor Conference Call
16/07/12
PXSCeasing to be a substantial holder
10/07/12
PXSBecoming a substantial holder
05/07/12
PXSCeasing to be a substantial holder
04/07/12
PXSProposed Issue of Performance Rights to CEO
02/07/12
PXSAppendix 3B - Grant of Employee Performance Rights
02/07/12
PXSAppendix 3B - Exercise of Employee Options
02/07/12
PXS +Becoming a substantial holder from UBS
29/06/12
PXSChange of Director's Interest Notice
28/06/12
PXSAppendix 3B
28/06/12
PXSPHARMAXIS WELCOMES BRONCHITOL PBS LISTING ANNOUNCEMENT
25/06/12
PXSCeasing to be a substantial holder
19/06/12
PXSBecoming a substantial holder
15/06/12
PXSAdditional Data Bronchitol Reduces Risk of Exacerbations
08/06/12PRICE SENSITIVE
PXSAppendix 3B - Exercise of Employee Options
01/06/12
PXSBronchitol Commercial Progress in Europe
01/06/12PRICE SENSITIVE
PXSAppendix 3B - Exercise of employee options
21/05/12
PXSPharmaxis Submits US New Drug Application for Bronchitol
21/05/12PRICE SENSITIVE
PXSAmended - Ceasing to be a substantial holder
16/05/12
PXSCeasing to be a substantial holder
10/05/12
PXSAppendix 3B Exercise of Employee Options
02/05/12
refresh Created with Sketch. REFRESH
 

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
HotCopper Highlights: Your most watched stocks for Week 48, 2024 Good afternoon, a happy end of the week, and welcome to HotCopper Highlights – I’m Jonathon Davidson. Let’s get into it.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor The ASX200 has been really flirting with the 8,500pts mark this week, notching an intraweek ATH of 8,476pts.
Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher Vitrafy Life Sciences Limited (ASX:VFY) has defied this month’s odds to become the only newly-listed Australian company to survive a surprisingly rough November (for newcomers, at least) without sagging below its IPO price.The cryopreservation biotech did give some back on Friday,...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.